pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)
MSD Merck Sharp
Merck Sharp and Dohme
Merck Sharp and is a pharma organization headquartered in EU. Primary therapeutic focus areas include Atherosclerosis, Non-small Cell Lung Cancer (NSCLC), Hypercholesterolemia, HIV infection, Acute and chronic Pain. Nova
WERFTESTRASSE 4, Lucerne, 6005, ch HQ
61 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- WERFTESTRASSE 4, Lucerne, 6005, ch
- Employees
- 61
- Programs
- 217
- Drugs
- 180
- Patents
- 0
MS201924_0001
Phase 1 · other · Metastatic or Locally Advanced Unresectable Solid Tumors
MS201924_0001 for Metastatic or Locally Advanced Unresectable Solid Tumors is a Phase 1 program (other) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Internal code MS201924_0001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Merck Sharp and Dohme
- Phase
- Phase 1
- Modality
- other
- Indication
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Status
- active
- Trials
- 1